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IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab
in patients with multiple sclerosis (MS).
OBJECTIVE To evaluate the effect of therapeutic choices on themean annualized relapse rate
and onmagnetic resonance imagingMS activity after 24 doses of natalizumab in patients
with relapsing-remitting MS.
DESIGN, SETTING, AND PARTICIPANTS The TY-STOP study, which recruited participants
between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care
outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic
resonance imagingMS activity after 24 doses of natalizumab.
INTERVENTIONS Natalizumab, no treatment, interferonbeta, glatiramer acetate, or fingolimod.
MAINOUTCOMESANDMEASURES Theprimary endpointwas themean annualized relapse rate.
Statistical analyseswere performed in 124patientswith complete follow-updata among 130
patientswhowere recruited and stratified into study groups. In the intent-to-treat group, the
decisionwasmade to continue or interrupt natalizumab after 24doses. In the as-treated group,
natalizumab continuers receivednatalizumab, natalizumab switchers changed to different
therapies, andnatalizumabquitters discontinuednatalizumabduring the study year.
RESULTS Nosignificant differences indemographic or baseline clinical characteristicswere found
among the studyparticipants. In the intent-to-treat group (n = 124), clinical (P = .004) and radio-
logic (P = .02)MSactivitywas significantly lower inpatients continuingnatalizumab (n = 43) than
inpatients interruptingnatalizumab (n = 81),with aprotective effect of natalizumabcontinuation
onbothoutcomes (odds ratio [OR],0.33; 95%CI,0.15-0.70 for clinical activity andOR,0.35; 95%
CI,0.15-0.79 for radiologic activity). In the as-treatedgroup (n = 124), clinical (P = .003) and radio-
logic (P = .03)MSactivitywas significantly lower innatalizumabcontinuers than innatalizumab
switchers or quitters, confirming aprotective effect of natalizumabon the risk of relapse in
natalizumabcontinuers comparedwithnatalizumabquitters (OR,4.40;95%CI, 1.72-11.23) and
natalizumab switchers (OR, 3.28;95%CI,0.99-10.79).Nodisease reboundwasobserved in
natalizumabquitters. After natalizumabdiscontinuation, 1 patient developedprogressive
multifocal leukoencephalopathyduring theobservationperiod,with complete recovery.
CONCLUSIONS AND RELEVANCE This study provides class III evidence of an increased risk of
MS activity resumption after natalizumab discontinuation. Therapy discontinuation after 24
doses in natalizumab-responding patients should be considered only if the risk of progressive
multifocal leukoencephalopathy is high and outweighs the benefits of continuing the drug.
TRIAL REGISTRATION Osservatorio Nazionale Sulla Sperimentazione Clinica dei Medicinali
No. 131/2010.
JAMA Neurol. doi:10.1001/jamaneurol.2014.1200
Published online June 30, 2014.
Editorial
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author: Luca Durelli,
MD, Division of Neurology,
Department of Clinical and Biological
Sciences, University of Turin, San
Luigi Gonzaga University Hospital, 10
Regione Gonzole, I-10043 Orbassano
(TO), Italy (luca.durelli@unito.it).
Research
Original Investigation
E1
Downloaded From: http://archneur.jamanetwork.com/ by a Universita Torino User  on 07/01/2014
Copyright 2014 American Medical Association. All rights reserved.
N atalizumab, a humanized anti–α4 integrin monoclo-nal antibody, is a highly effective treatment ap-proved for relapsing-remitting multiple sclerosis
(RR-MS).1-3 Althoughnatalizumab therapy iswell tolerated, it
can be associatedwith a rare serious and potentially fatal op-
portunistic infection of the central nervous system caused by
the John Cunninghamvirus (JCV) known as progressivemul-
tifocal leukoencephalopathy (PML).4-6The first episodesof this
adverseeffecthadaneffecton theevaluationof the safetypro-
file of natalizumab and led to the implementation of tools to
stratify patients according to their risk to ensure better thera-
peutic management. The increased frequency of PML cases
over time created serious concern in themedical community
and among patientswithMS and led the EuropeanMedicines
Agency(EMA)toestablishameticulousriskmanagementplan.7
According to this plan, patients are asked to provide consent
to continue natalizumab treatment after 24 doses and to re-
sign a standardized informed consent. Alternatively, patients
may consider switching to anyother treatment forMSor quit-
ting all therapies.
Few studies8-15 have attempted to evaluate the course of
clinical and radiologic (ie, magnetic resonance [MR] imaging)
MS activity after natalizumab discontinuation and to compare
this activity with that in patients continuing natalizumab.
Herein, we describe the results of a spontaneous, prospective,
multicenter, observational study aimedat evaluatingMSclini-
cal activity, determined by the mean annualized relapse rate
(ARR) and by disease progression measured on the Expanded
Disability Status Scale (EDSS) by Kurtzke,16 as well as by MR
imaging MS activity, in patients with RR-MS stratified accord-
ing to therapeutic choices after 24 doses of natalizumab.
Methods
Ethical committees of each participating hospital or univer-
sityapprovedthestudyprotocol.Thestudywasregisteredwith
theOsservatorioNazionale Sulla SperimentazioneClinica dei
Medicinali (No. 131/2010). All participating patients provided
written informed consent.
The TY-STOP study is a spontaneous, observational, pro-
spective multicenter trial. A total of 130 patients 18 years or
olderwith clinically definite RR-MSwho received 24 doses of
natalizumab,hadclinical andMRimagingMSstability, andhad
at least 1 MR image within 10 days after 24 doses of natali-
zumabwererecruitedfrom8ItalianMScenters (secondarycare
outpatient clinics) betweenOctober 22, 2010, andOctober 22,
2012, and were followed up for 1 year.
Clinical MS stability was defined as the absence of docu-
mented relapses and the absence of EDSS progression during
the preceding 6months.Magnetic resonance imagingMS sta-
bility was defined as the absence of new or enlarging T2-
weighted lesions compared with MR imaging acquired 1 year
before study entry and the absence of gadolinium-enhancing
lesions on baseline MR imaging.
Exclusion criteria were pregnancy, severe depression, al-
cohol or drug addiction, and any clinical condition in addi-
tion toMS. Data for each patient were collected by the evalu-
atingneurologist (M.C., S.F.D.M.,R.L.,A.G., S.R., F.V., P.C., and
D.P.) in an electronic case report form located on the server of
the coordinating center (DivisionofNeurology,Departmentof
Clinical andBiological Sciences,University ofTurin, SanLuigi
Gonzaga University Hospital, Orbassano, Italy).
After 24 doses of natalizumab, treatment was redis-
cussed with individual patients in accord with EMA
recommendations.7 The treatment options offered to pa-
tients were (1) continuing intravenous natalizumab (300mg)
every 28 days, (2) switching to another disease-modifying
therapy (DMT), (3) discontinuing all treatment, or (4) begin-
ning intravenous mitoxantrone hydrochloride (12 mg/m2 ev-
ery month or every 3 months). Alternative DMTs were (1) in-
terferon beta-1a (intramuscular 30 μg once weekly or
subcutaneous 22 or 44μg 3 timesweekly) or subcutaneous in-
terferon beta-1b (250 μg every other day), (2) glatiramer ac-
etate (subcutaneous 20 mg every day), or (3) oral fingolimod
(0.50 mg every day).
Interferon betawas not considered an option for patients
with knownpositivity for serumanti–interferonbeta neutral-
izing antibodies. The chosen treatment was begun immedi-
ately after natalizumab discontinuation, except for fingoli-
mod, which requires a 3-month washout period according to
the manufacturer’s recommendations.
Patientswere examinedafter 24dosesofnatalizumaband
every 3 months thereafter. Assessments included a physical
examination and a neurologic examination with the evalua-
tion of the EDSS. All evaluating neurologists at the ItalianMS
centersparticipating in this studywere trained touse theEDSS
scale tomeasure disability. Safety assessments, performed at
each visit, included vital signs, concomitant medication use,
and collection of information on any adverse effect. Patients
also underwent hematologic and biochemical tests, includ-
ing tests of liver and kidney function, every 3 months.
Proton density T2-weighted and pre-post gadolinium-
enhanced T1-weighted MR images were obtained at months
0, 3, 6, and 12 after 24 doses of natalizumab. TheMR imaging
was scheduled at 3-month intervals to detect possible dis-
ease reactivation in patients discontinuing natalizumab and
to monitor for the occurrence of PML in patients continuing
treatment with the monoclonal antibody. Repositioning was
achieved using internal anatomical landmarks located on T1-
weighted axial, coronal, and sagittal scouts. The MR images
were evaluated for radiologicMS activity during the observa-
tion year (annual MR imaging MS activity). Magnetic reso-
nance imaging MS activity in the follow-up year was defined
as any new or enlarging T2-weighted lesion compared with
lesions in the previous MR images or any gadolinium-
enhancing lesion.
In the event of exacerbationsor adverse effects during the
follow-up period, patients were asked to contact the referral
MS center, and exacerbationswere treatedwith high-dose in-
travenousmethylprednisolonesodiumsuccinate ifneeded.An
exacerbation was defined as the occurrence of a new neuro-
logic symptom or a worsening of an old one, with an objec-
tive changeof at least 1 point on theEDSS,which lastedat least
24hours in the absenceof fever and followedaperiodof clini-
cal stability or improvement of at least 30 days.
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Theprimaryoutcomeof the studywas themeanARR.An-
nualMR imagingMSactivityand the3-monthconfirmedmean
EDSS at 1 year were the secondary outcomes.
For thestatistical analysis,patientsweredivided intostudy
groupsaccordingtothefollowing2criteria: (1) thedecisionabout
whether to continue or interrupt natalizumab treatment after
24doses (intent-to-treat [ITT] group) and (2) the treatment pa-
tients actually received during the follow-up year (some pa-
tients reverted to taking natalizumab after having decided to
stop it) (as-treated [AT]group).Patients in the lattergroupwere
further divided into the following 3 subgroups based onwhen
and for how long they received natalizumab during the 1-year
follow-upperiod: (1)patientscontinuingnatalizumabduringthe
entire observation year (natalizumab continuers); (2) patients
switching to different DMTs, including natalizumab (natali-
zumab switchers); and (3) patients discontinuing natalizumab
during the entire observation year (although they could have
received another DMT) (natalizumab quitters).
Normality of continuous variables was evaluated by an
analysisof thehistogramsandwasconfirmedby theKolmogo-
rov-Smirnov test. Demographic and disease characteristics at
baseline were summarized as numbers (percentages), means
(SDs), andmedians (ranges). Any relationship between treat-
ment group and age (at baseline and age at onset) was as-
sessed by linear regression analysis. Treatment group differ-
ences in EDSS score, body mass index, disease duration, and
ARR before the study were evaluated with the nonparamet-
ricMann-Whitney test orKruskal-Wallis test. χ2 Test or Fisher
exact testwasperformed to compare categorical variables and
particularly to evaluate any association between treatment
group and types of therapy used before natalizumab treat-
ment. Any association between treatment group and ARR at
the end of the study was assessed by negative binomial re-
gressionanalysis.17Binary logistic regressionwasusedtoverify
whether treatment group was a statistically significant pre-
dictor of MR imaging MS activity. Data are expressed as odds
ratios (ORs) with 95% CIs.
Statistical analyses were performed using commercially
available software (SPSS version 20; IBM). All statistical tests
were 2-sided, and the significance level (α error)was set at .05.
Results
In total, 130patientswith clinically andMR imaging stableMS
were enrolled in the study, and 124 (95.4%) of themhad com-
pleted the entire clinical follow-up period at the time of the
analysis (Figure). Table 1 summarizes their demographic and
baseline clinical characteristics (EDSS score, disease dura-
tion, ARR,MR imagingMSactivity, and therapybefore natali-
zumab). Following EMA recommendations,7 natalizumab
therapy was rediscussed after 24 doses, considering the in-
creased risk of PML6,18,19 and the risk of clinical or radiologic
reactivation of MS.8,9,11 At study baseline (ie, after receiving
24 doses of natalizumab), 81 patients (65.3%) decided to in-
terrupt natalizumab therapy, while 43 patients (34.7%) de-
cided to continue it and signed a second informed consent
form. Their JCV antibody status and prior immunosuppres-
sive therapyhadno role in this decisionbecause thesehadnot
been characterized as risk factors for the occurrence of PML
at the time of study recruitment.6 No significant differences
were observed between these 2 groups of patients. In addi-
tion, no significant differences were observed in demo-
graphic andbaseline clinical characteristics between the6pa-
tients who did not complete the entire follow-up period and
the 124 patients who completed it (data not shown). There-
fore, all efficacy analyses were performed among 124 pa-
tients who completed the follow-up period.
Table 2 summarizes the results of the comparison of pa-
tients who decided to continue natalizumab compared with
those who decided to interrupt natalizumab therapy (ITT
group). During the 1-year observation period, the mean ARR
(OR, 0.33; 95%CI, 0.15-0.70;P = .004) andMR imagingMSac-
tivity (OR, 0.35; 95% CI, 0.15-0.79; P = .02) were lower for pa-
tients continuing natalizumab compared with patients inter-
rupting natalizumab.
Among natalizumab switchers (Figure), only 2 patients
were treated with fingolimod because the drug was regis-
tered in Italy during the last months of the recruitment
period.20 All natalizumab switchers who began natalizumab
again after a temporary discontinuation did so because ofMS
Figure. Enrollment of Patients in the Study
130 Patients enrolled in the study
124 Had 12 mo of clinical follow-up data
124 Included in the ITT group
43 Natalizumab
continuers
81 Natalizumab
interrupters
124 Included in the AT group
16 Natalizumab
switchers
35 Natalizumab
continuers
73 Natalizumab
quitters
6 Had not completed the entire
clinical follow-up period
Patients are shown according to the
intent-to-treat (ITT) group and the
as-treated (AT) group. Among
natalizumab switchers after 24 doses,
8 patients continued to receive
natalizumab for 1 or more doses,
stopping it thereafter, and the other 8
patients stopped natalizumab use
after the initial course of 24 doses
and began it later again.
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activity resumption. The results from the AT group (n = 124)
are summarized in Table 3. During the 1-year follow-up pe-
riod, the mean ARRwas about 3 times higher in natalizumab
switchers (OR, 3.28; 95%CI,0.99-10.79;P = .05) andmore than
4 timeshigher innatalizumabquitters (OR, 4.40; 95%CI, 1.72-
11.23; P = .002) compared with natalizumab continuers.
With regard to annual MR imaging MS activity, signifi-
cant differences were observed between natalizumab con-
Table 1. Demographic and Baseline Characteristics of the Patients
Variable
Total
(N = 124)
Natalizumab
Continuers
(n = 43)
Natalizumab
Interrupters
(n = 81) P Valuea
Age, y .22
Mean (SD) 38.71 (9.69) 37.36 (9.46) 39.52 (9.79)
Median (range) 38.00 (18.00-63.00) 37.00 (19.00-60.00) 39.00 (18.00-63.00)
Body mass indexb .22
Mean (SD) 23.62 (3.80) 22.99 (2.75) 23.97 (4.25)
Median (range) 23.40 (17.40-37.30) 22.90 (17.60-30.70) 23.70 (17.40-37.30)
Age at MS onset, y .80
Mean (SD) 26.60 (8.58) 26.85 (9.46) 26.45 (8.09)
Median (range) 26.00 (11.00-56.00) 25.00 (12.00-56.00) 26.00 (11.00-49.00)
Female sex, No. (%) 88 (71.0) 32 (74.4) 56 (69.1) .94
Disease duration, y .10
Mean (SD) 11.35 (6.87) 9.96 (5.85) 12.19 (7.32)
Median (range) 10.00 (0.00-31.00) 9.00 (2.00-24.00) 10.50 (0.00-31.00)
EDSS score .67
Mean (SD) 3.38 (1.69) 3.31 (1.65) 3.42 (1.73)
Median (range) 3.50 (0.00-7.00) 3.50 (1.00-7.00) 3.50 (0.00-6.50)
Annualized relapse rate
before natalizumab therapy
.12
Mean (SD) 2.00 (1.32) 2.29 (1.53) 1.84 (1.17)
Median (range) 2.00 (0.00-7.00) 2.00 (0.00-7.00) 2.00 (0.00-6.00)
MR imaging MS activity
before natalizumab therapy,
No. (%)
73 (58.9) 29 (67.4) 44 (54.3) .27
Previous therapy, No. (%) .38
Other 7 (5.6) 2 (4.7) 5 (6.2)
Glatiramer acetate 20 (16.1) 11 (25.6) 9 (11.1)
Intramuscular interferon
beta-1a
17 (13.7) 3 (7.0) 14 (17.3)
Interferon beta-1b 23 (18.5) 7 (16.3) 16 (19.8)
Subcutaneous interferon
beta-1a, 22 μg
13 (10.5) 3 (7.0) 10 (12.3)
Subcutaneous interferon
beta-1a, 44 μg
28 (22.6) 9 (20.9) 19 (23.5)
None 16 (12.9) 8 (18.6) 8 (9.9)
Abbreviations: EDSS, Expanded
Disability Status Scale; MR, magnetic
resonance; MS, multiple sclerosis.
a Statistically significant at P < .05.
bCalculated as weight in kilograms
divided by height in meters
squared.
Table 2. Analysis of the ITT Group
Variable
Natalizumab
Continuers
(n = 43)
Natalizumab
Interrupters
(n = 81) P Value
Discontinuations, No. (%) 8 (18.6) 8 (9.9) NA
EDSS score .23
Mean (SD) 3.36 (1.69) 3.80 (1.83)
Median (range) 3.50 (0.00-6.50) 3.50 (0.00-7.00)
Annualized relapse rate .004a
Mean (SD) 0.24 (0.48) 0.73 (0.85)
Median (range) 0.00 (0.00-2.00) 1.00 (0.00-4.00)
OR (95% CI) 0.33 (0.15-0.70) 1 [Reference]
MR imaging MS activity in the observation year .02a
No. (%) 11 (25.6) 39 (48.1)
OR (95% CI) 0.35 (0.15-0.79) 1 [Reference]
Abbreviations: EDSS, Expanded
Disability Status Scale;
ITT, intent-to-treat; MR, magnetic
resonance; MS, multiple sclerosis;
NA, not applicable; OR, odds ratio.
a Statistically significant at P < .05.
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tinuers (n = 35) and natalizumab quitters (n = 73). The latter
had a higher probability ofMR imagingMS activity compared
with the former (OR, 2.81; 95% CI, 1.17-6.74; P = .03).
At the end of the study, a decreasing trend in EDSS scores
was observed among the 3 groups of patients: natalizumab
switchers had the highest mean (SD) EDSS score (4.03 [1.76]),
whereas natalizumab continuers had the lowest mean (SD)
EDSS score (3.16 [1.69]). The differenceswere not statistically
significant (P = .14).
During the year before beginning natalizumab and dur-
ing the year after stopping natalizumab, no significant clini-
cal or radiologic rebound phenomena were observed among
natalizumab quitters. In particular, the ARRwas significantly
lower (P < .001) at the end of the study period than before the
group began natalizumab. We observed no significant differ-
ence in annual MR imagingMS activity before vs after natali-
zumab use among natalizumab quitters.
In the subgroup of patients who began interferon beta,
52.7% developed a flulike syndrome, 54.2% manifested bio-
humoral alterations, and 72.8% had injection site reactions.
Seventy-five percent of the participants who began glati-
ramer acetate developed injection site reactions. Among the
patients who began fingolimod, leukopenia and a significant
increase in liver enzyme levels were found in 3.5% and 12.9%
of cases, respectively.
One case of pyelonephritis was documented in the group
of patients continuing natalizumab. In addition, onemyocar-
dial infarction occurred in this group of patients.
Threemonths after natalizumabdiscontinuation, onepa-
tient had a generalized epileptic seizure associated with ex-
pressive aphasia. The MR imaging was consistent with PML,
and polymerase chain reaction testing for JCV DNA in the ce-
rebrospinal fluid was positive. The patient was treated with
plasmapheresis and mirtazapine, achieving complete remis-
sion of neurologic deficits (remission of aphasia and cessa-
tion of seizures). This patient’s EDSS score was 1.00 at base-
line and at 5 months after stopping natalizumab. The patient
then began treatment with glatiramer acetate. However, 10
months after interrupting natalizumab and when receiving
glatiramer acetate therapy, the patient had a clinical relapse
that caused a 1.00-pointworsening of the EDSS score, despite
the administration of high-dose corticosteroids.
Discussion
Ourspontaneous,prospective,observationalmulticenter clini-
cal andMR imaging study allowed us to evaluate the efficacy
of treatment options after 24 doses of natalizumab in pa-
tients with RR-MS. The results show that patients who con-
tinued natalizumab for the entire follow-up period fared sig-
nificantly better than those who completely stopped
natalizumab (despite receiving other DMTs) or thosewho be-
gan natalizumab again for somemonths during the 1-year ob-
servation period.
Natalizumab is themost effective drug for RR-MS.1 How-
ever, treatment with natalizumab may be associated with
PML.4,5 As of February 4, 2014, a total of 439 confirmed cases
ofnatalizumab-associatedPMLhadbeenreported,21 and itwas
shown that the risk of PML increases after 24 doses of natali-
zumab.Basedon thesedata, theEMAimplementeda riskmiti-
gation plan requiring neurologists to reevaluate natalizumab
treatment after 24 doses, and patients opting to continue re-
ceiving this drug for longer periods must sign a second in-
formed consent form.7
Data about the risk of clinical reactivation of MS after na-
talizumabdiscontinuationhave been inconsistent.8,9,11 Some
studies8,11 showed disease activity recurring approximately 5
to 6months followingnatalizumabdiscontinuation. The larg-
est cohort was analyzed in an 8-month retrospective study11
of clinical and MR imaging MS activity among 1866 patients
who had received at least 1 dose of natalizumab before dis-
continuing it. Recurrent disease peaked at 4 to 7months after
natalizumab interruption, regardless of the administration of
alternative DMTs for MS.
The evaluation of the efficacy of alternative therapeutic
strategies forpatientsdiscontinuingnatalizumabhasbeen the
goal of other studies, and the results have been controversial.
In 2 small prospective studies, 9 patients22 and 13 patients12
switched fromnatalizumab toa first-lineDMT(interferonbeta
or glatiramer acetate):most of the patients treatedwith inter-
feron beta remained free of clinical relapses, while the pa-
tients treated with glatiramer acetate showed a return of dis-
ease activity. Better results with glatiramer acetate used after
natalizumab interruption were shown in a 12-month study23
Table 3. Analysis of the AT Group
Variable
Total
(N = 124)
Natalizumab
Continuers
(n = 35)
Natalizumab
Quitters
(n = 73)
Natalizumab
Switchers
(n = 16) P Value
EDSS score .14
Mean (SD) 3.59 (1.77) 3.16 (1.69) 3.79 (1.82) 4.03 (1.76)
Median (range) 3.5 (0.0-7.0) 2.50 (0.00-6.00) 3.50 (0.00-7.00) 4.00 (1.00-6.50)
Annualized relapse rate .003a
Mean (SD) 0.56 (0.78) 0.17 (0.38) 0.75 (0.86) 0.56 (0.73)
Median (range) 0.00 (0.0-4.0) 0.00 (0.00-1.00) 1.00 (0.00-4.00) 0.00 (0.00-2.00)
Relative risk (95% CI) NA 1 [Reference] 4.40 (1.72-11.23) 3.28 (0.99-10.79)
MR imaging MS activity
in the observation year
.03a
No. (%) 50 (40.3) 10 (28.6) 36 (49.3) 4 (25.0)
OR (95% CI) NA 1 [Reference] 2.81 (1.17-6.74) 1.00 (0.25-3.94)
Abbreviations: AT, as-treated;
EDSS, Expanded Disability Status
Scale; MR, magnetic resonance;
MS, multiple sclerosis; NA, not
applicable; OR, odds ratio.
a Statistically significant at P < .05.
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prospectively following up 40 patients treated with glati-
ramer acetate after 12 to 18 months of natalizumab use. Ap-
proximately 60%of patients remained relapse free during the
observation period. Other studies13,24 evaluated the efficacy
of switching from natalizumab to fingolimod. In these stud-
ies, clinical or radiologic disease activity recurred in 40% to
50% of patients switching to fingolimod. However, the co-
horts in both studies were small (range, 22-36 patients), and
the lengthof timebetweendiscontinuingnatalizumabandbe-
ginning fingolimod could have affected the return of disease
activity, as suggested by other study15 findings.
In our observational, prospective study, the decision to
continueordiscontinuenatalizumabafter 24doseswasbased
onlyon theEMArecommendation toexercise care inprescrib-
ingnatalizumabbeyond24months.7 TheEMAstatement that
24monthsof treatment represent the crucial timewhen treat-
ment shouldbe rediscussed isprobably arbitrarybecausePML
canoccurmuchearlier than2years and thereafter.6,18,19 In any
case, following theEMA recommendationmeant that thedis-
tribution of our patients into the various therapy subgroups
was not biased by JCV antibody status or prior immunosup-
pressive therapy.
InourcohortofpatientswithRR-MSwhohadreachedclini-
cal and MR imaging stability of MS after 24 doses of natali-
zumab, the risk of relapsingwas about 3 timeshigher in natali-
zumab switchers (P = .05) and more than 4 times higher in
natalizumabquitters (P = .002)comparedwithnatalizumabcon-
tinuers. Annual MR imagingMS activity was also significantly
lower in natalizumab continuers than in natalizumab quitters
(P = .03).AlthoughEDSSscoresdidnotdifferbetweenthegroups
ofpatientsat thebeginningoftheobservationperiod,1year later
the mean EDSS score was lowest in natalizumab continuers,
likely suggesting a protective effect of natalizumab continua-
tion on disease progression. The difference in scores was not
statistically significant, anda longer follow-upperiod is neces-
sary for a significant effect to bemanifested.
Thephenomenonof reboundMSwasnot observed in our
study. Among natalizumab quitters, we observed a signifi-
cantly lower relapse rate after natalizumab discontinuation
compared with clinical activity before starting natalizumab
(datanot shown).Therefore,ourprospective study in this large
patient groupdoesnot confirm theoccurrenceof reboundMS
after stopping natalizumab that had been found in previous
retrospective or small cohort investigations8 but confirms the
results of prospective or larger studies.9,11
In our study, the incidence of adverse effectswas compa-
rable to that known for thevariousRR-MS treatments.25-27 The
one case of pyelonephritis and the one instance of myocar-
dial infarctionwere probably unrelated to natalizumab treat-
ment. Progressive multifocal leukoencephalopathy occurred
in one patient at 3 months after natalizumab discontinua-
tion: the patient subsequently achieved complete remission
of neurologic deficits following treatment with plasmapher-
esis and mirtazapine.
Conclusions
Our study shows that clinical and MR imaging MS reactiva-
tion occurs more frequently in patients stopping natali-
zumab than in those continuing treatment after 24doses. The
results froma large, prospectivemulticenter study suchas this
one can better translate into clinical practice than the results
fromsmall, single-center studies,particularly relative toahigh-
prevalencedisease suchasMS.28According toour results, con-
tinuing natalizumab seems to be the most efficacious thera-
peutic strategy inpatientswhohavealready received24doses
of the drug, although it may be associated with a risk of de-
veloping PML in patients previously exposed to JCV. There-
fore, any decision about the therapeuticmanagement of JCV-
positivepatientsafter 24dosesofnatalizumabshould take into
account the risk of disease reactivation associatedwithnatali-
zumab discontinuation and the risk of PML potentially asso-
ciated with prolonged natalizumab treatment. Careful indi-
vidual evaluation of PML risk based on the risk factors is
needed,18,19 and natalizumab discontinuation can be reason-
ably advised for patientswhose risk is considered toohigh. In
all other cases, natalizumab should be continued, with me-
ticulous monitoring of MR imaging to detect the occurrence
of possible PML at a subclinical stage.29,30
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